Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ultragenyx Pharmaceutical ( (RARE) ) has shared an announcement.
On March 12, 2026, Ultragenyx reported positive Phase 3 Enh3ance trial results for DTX301, its investigational AAV8 gene therapy for ornithine transcarbamylase deficiency, showing an 18% reduction in 24-hour plasma ammonia levels versus placebo at Week 36 and maintenance of average ammonia exposure within the normal range. Patients on DTX301 rapidly improved ammonia control despite reduced use of ammonia scavenger medications and higher protein intake, reported better symptom and daily living scores than placebo, and experienced fewer hyperammonemic crises and deaths, while safety remained consistent with earlier studies and the program is being advanced within existing spending plans and a goal of profitability in 2027.
The study’s planned second primary endpoint will assess reduction in treatment burden, including medication and dietary restrictions, across treated and placebo-crossover groups through 64 weeks, with data expected in the first half of 2027, potentially positioning DTX301 as a meaningful new option in OTC deficiency care. The company indicated that the conduct of this late-stage program aligns with its February 2026 financial guidance and is being managed to support its target of reaching profitability in 2027, underscoring both clinical and operational progress for stakeholders.
The most recent analyst rating on (RARE) stock is a Buy with a $74.00 price target. To see the full list of analyst forecasts on Ultragenyx Pharmaceutical stock, see the RARE Stock Forecast page.
Spark’s Take on RARE Stock
According to Spark, TipRanks’ AI Analyst, RARE is a Neutral.
The score is primarily held back by weak financial performance: large ongoing losses, significant cash burn, and a sharply reduced equity base. Technicals also remain unfavorable with the stock trading below major moving averages and negative MACD. Offsetting these risks, the latest earnings call provided constructive forward guidance on revenue growth and planned cost reductions aimed at reaching profitability in 2027, but execution and regulatory risks remain significant.
To see Spark’s full report on RARE stock, click here.
More about Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a biotechnology company focused on developing gene therapies and other treatments for rare metabolic and genetic diseases. Its pipeline includes investigational adeno-associated virus (AAV) gene therapies such as DTX301, which targets patients with ornithine transcarbamylase deficiency who remain symptomatic despite current standard-of-care drugs and strict dietary management.
Average Trading Volume: 2,838,056
Technical Sentiment Signal: Sell
Current Market Cap: $2.15B
For a thorough assessment of RARE stock, go to TipRanks’ Stock Analysis page.